Therapeutic implications of hepatitis C virus resistance to antiviral drugs. - Wikidata - wikimedia - TriplyDB

Therapeutic implications of hepatitis C virus resistance to antiviral drugs.

Therapeutic implications of hepatitis C virus resistance to antiviral drugs.

http://www.wikidata.org/entity/Q34409020

about

Hepatitis C Virus (HCV) Genotype 1 Subtype Identification in New HCV Drug Development and Future Clinical Practice Reliability and validity of a self-efficacy instrument for hepatitis C antiviral treatment regimens.Hepatitis C viral heterogeneity based on core gene and an attempt to design small interfering RNA against strains resistant to interferon in rawalpindi, pakistan.IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin.Human Transbodies to HCV NS3/4A Protease Inhibit Viral Replication and Restore Host Innate Immunity Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C.Impact of HCV genetic differences on pathobiology of disease.Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.Hepatitis C variability, patterns of resistance, and impact on therapy Hepatitis C virus subtyping based on sequencing of the C/E1 and NS5B genomic regions in comparison to a commercially available line probe assay.Structural evaluation of the peritubular sheath of rat's testes after administration of ribavirin: A possible impact on the testicular function.Quasispecies and Drug Resistance

P2860

Q27490447-C18FABB9-A2FC-47F4-8E61-996967BDFB6D Q35906682-22ACC329-30A3-4B6F-977A-405D9F2A3FD3 Q36142763-475490EE-4317-494E-8C31-616E650E0243 Q36949481-2DF7C81B-13C9-434F-87DE-557832EB26E0 Q37208481-36E5157A-E0CF-4C51-97F9-163AD294C662 Q37263865-B56BBFD7-6275-41C8-8B93-456B8C493A93 Q37929753-0A764E0F-6D72-4F82-9077-6348DE90D7B1 Q37996076-9787EA86-47BA-494C-A934-3875A05E12E3 Q39576325-CED10E8E-07E8-497E-8C68-D03819328FE1 Q42270437-0214BF72-709A-4332-A208-573D730823C6 Q46198512-6DB8AAA7-4A93-49CB-83DE-74F658B1A0C2 Q56957250-B8BE5ED2-D4B7-4F9A-8D6C-268115148C8D

P2860

Therapeutic implications of hepatitis C virus resistance to antiviral drugs.

http://www.wikidata.org/entity/Q34409020

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Therapeutic implications of hepatitis C virus resistance to antiviral drugs.

@ast

Therapeutic implications of hepatitis C virus resistance to antiviral drugs.

@en

Therapeutic implications of hepatitis C virus resistance to antiviral drugs.

@nl

type

label

Therapeutic implications of hepatitis C virus resistance to antiviral drugs.

@ast

Therapeutic implications of hepatitis C virus resistance to antiviral drugs.

@en

Therapeutic implications of hepatitis C virus resistance to antiviral drugs.

@nl

prefLabel

Therapeutic implications of hepatitis C virus resistance to antiviral drugs.

@ast

Therapeutic implications of hepatitis C virus resistance to antiviral drugs.

@en

Therapeutic implications of hepatitis C virus resistance to antiviral drugs.

@nl

P1433

Q34409020-020ECEC1-86FB-4276-8483-99B1E786EA06

P1476

Q34409020-B84CD601-FA07-4A0E-9DD2-A105D8DCC15E

P2093

Q34409020-0A8B5743-B490-477D-A186-E27CFE4A372C

P2860

Q34409020-0053E500-F755-4064-847B-A953ADEE516E

Q34409020-00CB7471-9A6C-4A9F-9E21-BB0137899DF1

Q34409020-00DD7186-14D7-4919-8980-9F600B9DEE90

Q34409020-03A4ED8D-1840-4DA6-9610-D07389364616

Q34409020-058756D4-F6CC-49AF-BBDB-74F015899888

Q34409020-05FDC5FD-DA39-486A-AF5F-F6028936386D

Q34409020-0879800A-78B8-489D-A744-4C6F5FC90357

Q34409020-0C15928E-016F-4165-A35A-C63967E1E927

Q34409020-0C36536B-F232-4F35-A49A-C76A0789873B

Q34409020-0CCC7A4E-7C1E-4772-A4B3-C28B5DDE3DFA

P304

Q34409020-AFE63464-339A-4B13-8622-9EAEAD847693

P31

Q34409020-B235C335-9FFC-4FBF-8B45-CDFDF7F466C1

Q34409020-ca8095fa-fe07-4dd8-97e7-2fd10c4394c6

P356

Q34409020-5E1497BE-1A07-4D5A-A1D0-0A7822D4951D

P433

Q34409020-DC027068-89DF-4A71-9CA8-BD34B42035ED

P478

Q34409020-718BEAE8-23A0-4073-A222-4C38BAE416DA

P50

Q34409020-388F1819-87B2-43A2-97E5-6F3735FBFDFB

P577

Q34409020-99B711A4-FD7A-4642-9C36-EE1036BB23E9

P698

Q34409020-DD2346FA-37FC-4B49-A245-21A9B0E62D3A

P932

Q34409020-34A63D42-2B06-4344-9A61-8529CB1CEA9D

P356

1756283X09336045

P1433

Therapeutic Advances in Gastroenterology

P1476

Therapeutic implications of hepatitis C virus resistance to antiviral drugs.

@en

P2093

Jean-Michel Pawlotsky

http://www.w3.org/2001/XMLSchema#string

P2860

RNA virus error catastrophe: direct molecular test by using ribavirin

Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors

Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations

Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy

Effect of alpha interferon on the hepatitis C virus replicon

Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system.

Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons.

Selection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymerase Inhibitors of the Hepatitis C Virus

Alpha Interferon Inhibits Hepatitis C Virus Replication in Primary Human Hepatocytes Infected In Vitro

Molecular Mechanism of a Thumb Domain Hepatitis C Virus Nonnucleoside RNA-Dependent RNA Polymerase Inhibitor

P304

205-219

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1756283X09336045

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Michel Pawlotsky

P577

2009-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21180544

http://www.w3.org/2001/XMLSchema#string

P932

3002526

http://www.w3.org/2001/XMLSchema#string